Eris Lifesciences — Multiple Levers To Enhance Growth Prospects: Nirmal Bang

Nirmal Bang Report

We hosted the management of Eris Lifesciences Ltd. at our annual investors’ conference to discuss the company’s business outlook. The management sees multiple levers in the existing business to grow by 14-15% annually with 36-37% Ebitda margin in the next two-three years.

For FY24, the company expects the Dermatology segment to clock revenue of ~Rs 4 billion with gross margin of 78-80% and Ebitda margin in the vicinity of company-level Ebitda margin (Oaknet margins ~24% in FY23).

In the Insulin business, the company is confident of achieving breakeven in FY24, led by scaling up of existing products and new launches. Overall margins are expected to improve from here on mainly on the back of:

1. Sharp improvement in Oaknet margins and MR productivity following the consolidation of acquired brands from Dr. Reddy’s Laboratories Ltd. and Glenmark Pharma Ltd., shifting to in-house manufacturing and synergy benefits with standalone business,

2. Reduced losses in the Insulin segment (expected to reach breakeven in FY24) and

3. operational leverage, especially driven by scale-up in new launches.

We like Eris due to its pure domestic theme, specialty focus, strong financials, healthy balance sheet and high return ratios.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.